Release Date: May 30, 2025
Expiration Date: May 30, 2026
Activity Overview
Breast cancer encompasses a diverse and complex group of diseases, with ongoing advances in detection, diagnosis, and multimodal treatment reshaping care. As our understanding of tumor biology deepens and standards of care evolve, so do the clinical questions and challenges faced by practitioners. Focused, case-based education is essential to support the integration of the latest evidence into everyday practice.
This Clinical Case Vignette Series™ offers a dynamic review of key insights from the 42nd Annual Miami Breast Cancer Conference®, which took place in March 2025. Through engaging expert interviews, the program highlights real-world clinical scenarios and explores how emerging data and evidence-based strategies are improving outcomes. Designed for clinicians who missed the live event—or those seeking to reinforce their learning—this activity delivers timely, practice-relevant education on the most pressing issues in breast cancer management.
Target Audience
This educational program is directed toward medical, radiation, and surgical oncologists whose primary practice focus is breast cancer and who intend to reinforce their knowledge base and expand their expertise in breast cancer diagnosis, treatment, and management.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe how to use validated genomic and molecular biomarkers and appropriate imaging techniques to enhance tumor evaluation and inform treatment decisions for patients with breast cancer
- Apply advances in surgical and radiation therapy options to improve breast cancer patient outcomes, emphasizing a multidisciplinary approach
- Integrate clinical trial evidence on established and emerging systemic therapies for early-stage and advanced breast cancers
- Personalize systemic treatment strategies for early-stage or advanced/metastatic breast cancer based on patient-specific factors, tumor characteristics, efficacy, safety data, and evolving guidelines
- Review clinical trials of novel therapies for eligible patients with breast cancer
- Implement multidisciplinary strategies to prevent, manage, and mitigate treatment-related adverse effects in patients with breast cancer, ensuring optimal outcomes and quality of life

Reshma Jagsi, MD, DPhil
Lawrence W. Davis Professor
Chair, Department of Radiation Oncology
Emory University School of Medicine
Winship Cancer Institute
Atlanta, GA
Reshma Jagsi, MD, DPhil, has no relevant financial relationships with ineligible companies.

Kevin Kalinsky, MD, MS
Professor, Department of Hematology and Medical Oncology
Director, Breast Medical Oncology
Director, Glenn Family Breast Center
Louisa and Rand Glenn Family Chair in Breast Cancer Research
Winship Cancer Institute of Emory University
Atlanta, GA
Disclosures: Grant/Research Support: AstraZeneca; Biotheranostics; Cyclocel; Eli Lilly; Eisai; eFFECTOR Therapeutics; Gilead; Immunomedics; Merck; Novartis; Pfizer; Prelude Therapeutics; RayzeBio; Regor; Seattle Genetics.

Hope S. Rugo, MD, FASCO
Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology & Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA
Professor Emeritus, UCSF
Disclosures: Grant/Research Support: Ambrx; AstraZeneca; Daiichi Sankyo, Inc; F. Hoffmann-La Roche AG/Genentech, Inc; Gilead Sciences, Inc; Lilly; Merck & Co, Inc; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Stemline Therapeutics. Consultant: Napo Therapeutics; Puma Biotechnology; Sanofi. Honoraria: Chugai; Mylan/Viatris.

Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS
Olga Keith Wiess Chair of Surgery
Professor and Chief, Section of Breast Surgery
Co-director, Lester and Sue Smith Breast Center
Leader, Breast Cancer Program
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX
Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS, has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC, (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.

GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here



